Goldman Sachs Initiates Coverage On Natera with Buy Rating, Announces Price Target of $90
Goldman Sachs analyst Matthew Sykes initiates coverage on Natera (NASDAQ:NTRA) with a Buy rating and announces Price Target of $90.
Morgan Stanley Maintains Overweight on Natera, Lowers Price Target to $110
Morgan Stanley maintains Natera (NASDAQ:NTRA) with a Overweight and lowers the price target from $118 to $110.
Natera Q4 EPS $(1.48) Misses $(1.31) Estimate, Sales $173.00M Beat $168.55M Estimate
Natera (NASDAQ:NTRA) reported quarterly losses of $(1.48) per share which missed the analyst consensus estimate of $(1.31) by 12.98 percent. This is a 66.29 percent decrease over losses of $(0.89) per share from the same
Natera’s Debt Overview
Over the past three months, shares of Natera (NASDAQ:NTRA) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows.
Natera Reports Expansion Into Early Cancer Detection Market
Dr. Alexey Aleshin to take on new role as GM of early cancer detection at Natera
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, today announced its
Medicare Coverage For Natera’s Signatera For Pan-Cancer Immunotherapy Monitoring
CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc’s (NASDAQ:NTRA)…